Abstract
Cell cycle disorder is a marker of cancer and has become a key point in the mechanism of endocrine resistance in advanced estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER-2-) breast cancer. The combination of cyclin dependent kinase (CDK) 4/6 inhibitors and endocrine therapy in treatment of ER+/HER-2- breast cancer has experienced rapid development and has been commercialized in many countries. This review will describe the mechanisms of action of CDK4/6 inhibitors and their development in advanced ER+/HER-2- breast cancer. Key words: Breast neoplasms; Cyclin dependent kinase 4/6
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
